uniQure Archives

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock exchange in the world, based in New York, and the largest for high-tech companies. It seems to be the real test for a European biotech to […]

February 23, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 6 Nov 2015

Biotech of the Week: Synpromics, the Scottish company enabling precise Gene Expression

This week we leave the wonderful weather of Mallorca and head North, through France, England and across Hadrian’s Wall where we land in the capital city of Scotland, Edinburgh. This city is famous for many things, being one of the most haunted cities in the world to being built on an extinct volcano however, it […]

November 6, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Sep 2015

UniQure’s cure for rare Lysosomal disease ready for phase III trial

UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial targeting a rare Lysosomal disease. This has granted fast-track approval to launch its phase III trial for children with Sanfilippo Type B (MPS-III) in collaboration with France’s Institut Pasteur. UniQure is the Amsterdam gene-therapy biotech with a lot going on. Last year […]

September 22, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Aug 2015

FDA shelves UniQure’s Glybera – will the Gene therapy once reach the US market?

The €1.1M drug Glybera was the first gene therapy on the European market. UniQure wants to sell it in the US too, but the FDA makes it much more difficult than expected. UniQure’s financial report of the first half of 2015 shows good results, cash and cash equivalents of the company increased to €181.9M, compared with […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

A Tale of Love for UniQure and Bristol-Myers Squibb

In May, Bristol-Myers Squibb (BMS) nailed down the exclusive access to uniQure’s gene therapy platform to treat cardiovascular diseases. Everything seems to work out fine as BMS paid $53M (€47M) for three new targets and additional shares to own nearly 10% of the company. UniQure is a Dutch pioneer in the field of gene therapy. It […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 7 Apr 2015

A New Key Strategic Collaboration Between BMS and UniQure

Last month, Bristol-Myers Squibb (BMS) and UniQure, the Dutch pioneer in human gene therapy, were at the forefront of the scene after having agreed on two collaborations, respectively, an agreement between Bavarian Nordic & BMS and a collaboration between Sympromics & UniQure. A few days ago, they announced an exclusive strategic collaboration to develop gene therapies for cardiovascular […]

April 7, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Mar 2015

Synpromics and UniQure, new Collaboration in Gene Therapy.

Synpromics has formed a collaboration with uniQure, the Dutch pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene therapies to liver. Synpromics, a leading synthetic biology company, will use its unique approach to develop synthetic promoters with upregulated, liver cell specific, activity whilst also decreasing the promoter molecular […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Dec 2014

Forbion Capital Partners: a Leading European Biotech VC is rising!

Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, sold PneumRx of its portfolio, to BTG plc, the UK-based specialist healthcare company for an initial cash consideration of €186M and up to €199M in performance-related future milestone payments. PneumRx is a growing interventional pulmonology business which owns, manufactures and distributes the RePneu Coil […]

December 5, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 1 Dec 2014

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

What could you buy with €1,1M euros? A house? Or a single prescription for a new drug… The first gene therapy drug “Glybera” is set to go on sale in Germany with a €1.1 million price tag, a new record for a medicine to treat a rare disease. And this drug from UniQure is not the only one […]

December 1, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 20 Aug 2014

uniQure acquires the gene therapy start-up InoCard

uniQure, a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease […]

August 20, 2014 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us